Use

AlloSure Kidney is a non‑invasive, transplant‑specific donor‑derived cell‑free DNA (dd‑cfDNA) blood test designed for earlier detection of kidney allograft injury and rejection. It analyzes SNPs across all 22 somatic chromosomes to quantify dd‑cfDNA levels, which serve as a leading indicator of graft injury. Elevated AlloSure levels are highly associated with all types and severities of kidney rejection, independently of standard clinical parameters, and provide improved detection and risk stratification over traditional markers such as serum creatinine, DSA, eGFR, proteinuria, and biopsy. It enables clinicians to detect molecular rejection prior to histological injury and clinical signs, improving early intervention and graft surveillance outcomes. This assay has been validated in large real‑world and prospective studies, including ADMIRAL and KOAR, and may elevate months earlier than detectable by DSA or biopsy. Lower dd‑cfDNA levels offer high negative predictive value. Clinical utility is further enhanced by integration within longitudinal monitoring and AI‑derived insights via AlloSure Plus.